NCT01285232

The Effect of Anakinra on Insulin Secretion

The Effect of Interleukin-1 Receptor Antagonist on Insulin Secretion in Subjects With Beta Cell Dysfunction

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Rationale: Once diabetes develops, β-cell function progressively deteriorates and therapeutic approaches that prevent of delay loss of β-cell function are needed in the treatment of type 2 diabetes mellitus. Recent findings suggest that interleukin-1 (IL-1) may be involved in the progressive β-cell dysfunction in type 2 diabetes mellitus. Objective: to determine whether blocking IL-1β by recombinant human IL-1ra (anakinra) improves beta-cell function in subjects with β-cell dysfunction.

Conditions

• Glucose Intolerance
• Impaired Insulin Secretion
• Diabetes Mellitus Type 2

Interventions

Type	Name	Description
DRUG	Anakinra	150 mg sc once daily during four weeks

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-03-01
• Completion: 2012-12-01
• First posted: 2011-01-27
• Last updated: 2012-03-26

Locations

1 site across 1 country: Netherlands